Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
Idiopathic Membranous Nephropathy
About this trial
This is an interventional treatment trial for Idiopathic Membranous Nephropathy focused on measuring Idiopathic Membranous Nephropathy, Treatment, Tacrolimus, Cyclophosphamide
Eligibility Criteria
Inclusion Criteria: Biopsy-proven idiopathic membranous nephropathy Nephrotic syndrome with proteinuria ( > 4 g/day) and serum albumin < 30 g/dl Age 18-60 years with informed consent Exclusion Criteria: Patient with abnormal liver function tests Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days Active/serious infection Patient with hepatitis B surface antigen or who is hepatitis C antibody positive Patient who is diabetic Patient is allergic or intolerant to macrolide antibiotics or tacrolimus
Sites / Locations
- Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
- Research Institute of Nephrology, Jinling Hospital
Arms of the Study
Arm 1
Active Comparator
FK506